CPD Plasma Is Getting Scarce — Why IVD Labs Are Switching to Citrate and Apheresis Plasma
CPD plasma was the default validation matrix in diagnostics for one reason: it was cheap and available in bulk. Both of those advantages are fading. Here is what is driving the shortage, how citrate and apheresis plasma compare as replacement matrices, and what the transition means for your IVDR validation programme.
Why CPD Plasma Became the Standard for IVD Validation
Anticoagulant Citrate Phosphate Dextrose (CPD) plasma is a by-product of whole blood donations. When a donor gives a standard whole-blood unit, the plasma fraction — anticoagulated with CPD solution at a 1:7 ratio — is separated after centrifugation. For decades, European blood banks produced it in large volumes, and the surplus that was not earmarked for fractionation (albumin, immunoglobulins, clotting factor concentrates) flowed into the diagnostic raw material market at low cost.
For IVD manufacturers validating immunoassays, haematology analysers, coagulation platforms and clinical chemistry methods, CPD plasma offered a practical compromise: it was human-derived, available in bulk, and cheap enough to use liberally across method development and lot release testing — even where it was not the closest matrix match to the intended clinical sample type.
Why CPD Plasma Supply Is Shrinking — and Will Not Recover
Three structural shifts are reducing CPD plasma availability across the EU, and none of them are temporary.
1. Blood banks are switching from whole blood to apheresis collection
Apheresis allows a single donor to give two to three times the plasma volume of a whole-blood donation in one session, while also enabling targeted component collection (platelets, plasma, red cells separately). As national blood services modernise their collection infrastructure, apheresis is replacing conventional whole-blood donation for plasma procurement. The CPD anticoagulant used in whole-blood bags is not part of the apheresis workflow — apheresis machines use citrate or ACD-A instead.
2. Remaining CPD plasma goes to fractionation first
The plasma fractionation industry — producing albumin, intravenous immunoglobulins (IVIg) and clotting factors — is growing steadily with increased demand from ATMP manufacturing, immunodeficiency treatment and haemophilia care. Fractionators hold long-term supply contracts with blood services and take priority. The residual CPD plasma reaching the IVD raw material market is shrinking, and the lots available are increasingly heterogeneous in quality and lot size.
3. Whole blood donation volumes are declining in DACH and Western Europe
Demographic trends, changing donor behaviour and reduced walk-in donation frequency mean fewer whole-blood units are collected per year across Germany, Austria and Switzerland. Fewer donations directly translate to fewer CPD bags and less surplus plasma reaching the research and diagnostic supply chain.
CPD Plasma vs. Citrate Plasma: What Actually Changes in Your Assay
CPD and citrate plasma are not interchangeable in every application. Understanding the matrix differences is essential before bridging studies or revalidation work begins.
| Parameter | CPD Plasma | Sodium Citrate Plasma (3.2 % / 3.8 %) |
|---|---|---|
| Anticoagulant components | Citrate + Phosphate + Dextrose | Sodium citrate only |
| Glucose content | Elevated — dextrose adds ~20–25 mM glucose to the plasma | Physiological glucose level |
| Phosphate load | Elevated — can affect phosphate-sensitive assays | No additional phosphate |
| Calcium chelation | Citrate chelates Ca²⁺ — not reversible without recalcification | Citrate chelates Ca²⁺ — reversible by adding CaCl₂ |
| Coagulation factor integrity | Preserved if frozen quickly | Preserved if frozen quickly; preferred for PT/APTT assays |
| Anticoagulant:blood ratio | 1:7 (fixed by bag volume) | 1:9 for 3.2 % sodium citrate (standard) — consistent |
| Collection method | Whole blood only | Whole blood or apheresis |
| Typical lot volume | Declining — increasingly fragmented lots | Scalable — especially via apheresis (600–800 mL per session) |
| Supply outlook (EU) | Tightening — structural decline expected to continue | Stable and growing with apheresis infrastructure investment |
| Cost trend | Rising as availability drops | Competitive — especially for apheresis bulk volumes |
The most practically relevant difference for immunoassay developers is the glucose artefact from the dextrose component of CPD. If your assay measures glucose directly, or if elevated glucose in the matrix influences antibody binding kinetics or enzyme activity, CPD plasma was never the right choice — it was just the convenient one. Citrate plasma eliminates this variable entirely.
Why Apheresis Plasma Is the Long-Term Answer
Plasmapheresis — automated plasma collection directly from the donor, without whole-blood donation — addresses the volume and consistency problems that make CPD plasma increasingly unsuitable as a production matrix.
Higher volume per donor unit
A single apheresis session yields 600–800 mL of plasma from one donor, compared with roughly 200–250 mL of plasma recovered from a standard whole-blood bag. For IVD manufacturers building large reference pools or producing calibrators and controls at scale, apheresis plasma dramatically reduces the number of donor units required per production lot — which simplifies donor screening, traceability and lot documentation.
Better between-lot consistency
Because each apheresis session produces a higher-purity, higher-volume unit from a single draw — without the concentration and processing variability inherent in whole-blood separation — lot-to-lot consistency is markedly better. For calibrator and control manufacturing, where tight protein concentration ranges are critical, this consistency directly reduces the number of bridging lots required over a product’s lifecycle.
Anticoagulant is citrate or ACD-A — not CPD
Apheresis machines use sodium citrate or anticoagulant citrate dextrose formula A (ACD-A) as the anticoagulant — not CPD. This means apheresis plasma inherits all the matrix advantages of citrate plasma: no phosphate, no dextrose artefact, reversible calcium chelation. For labs that have already specified citrate plasma in their validation protocols, apheresis plasma is a direct upgrade in scale, not a matrix change requiring revalidation.
EU origin with full documentation
Apheresis plasma sourced from certified EU donor centres — including Poland, which operates a well-established plasma apheresis network — is available with full lot traceability, donor viral screening (HIV, HCV, HBV, syphilis per EDQM and EU Blood Directive standards), Certificate of Analysis, and MSDS. EU origin also simplifies regulatory dossiers under IVDR, which increasingly scrutinises the origin and documentation of biological raw materials used in manufacturing.
What the Switch Means for Your IVDR Validation Programme
Changing the matrix used in IVD validation is not a like-for-like substitution — it is a design input change that triggers a defined change control and, in most cases, a bridging study. Under IVDR (EU) 2017/746, manufacturers are required to maintain the technical documentation of their devices, including evidence that the performance characteristics established in clinical validation remain valid after any change to critical raw materials.
The most important action is not to wait until your current CPD plasma supply runs out. Labs that begin matrix comparison work now — while CPD is still available as a reference — will have the bridging data they need to transition smoothly. Labs that wait will face validation gaps at the worst possible time: when supply is most constrained and lot-to-lot comparability is hardest to establish.
Transition checklist — CPD to Citrate/Apheresis Plasma
- Identify all assays currently validated using CPD plasma as the primary matrix
- Assess whether glucose or phosphate content of CPD could have been an active matrix variable in any of those assays
- Source small-volume citrate plasma (3.2 % sodium citrate, pooled, EU origin) for initial side-by-side comparison runs
- Design a bridging study: run both matrices against the same reference panel and compare key performance metrics (accuracy, precision, linearity, interference)
- Document the bridging data in your technical file and update your change control record
- Qualify a long-term citrate or apheresis plasma supplier with defined lot notification, CoA provision, and supply assurance commitments
- Consider reserving an initial bulk lot of apheresis plasma to freeze and hold as a stable reference pool across multiple lot releases
EU-Origin Citrate & Apheresis Plasma — No Minimum Order
Pooled and single-donor citrate plasma (3.2 % / 3.8 %), apheresis bulk volumes, and ACD-A format — sourced from certified EU donor centres, shipped from Germany. Full documentation per lot: CoA, CoO, viral screening records, MSDS.
View Plasma Portfolio Request a Sample Lot
English 
Deutsch